TICKERNERD
Menu
ARWRARWRHealthcare · Biotechnology

ARWR Stock Forecast: Arrowhead Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$86
+1.61% on the day

The 12 Wall Street analysts covering Arrowhead Pharmaceuticals, Inc. hold a median 12-month price target of $100 — +16.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 1 Aug 2026 — in the upper half.

Market cap
$11.9B
Ticker Nerd rank
63 / 100
Median analyst target
$100
Analysts covering
12
Total return, dividends reinvested
1W
+0.6%
1M
+2.4%
YTD
+29.6%
1Y
+439.9%
From 52W high
−3.0%
From 52W low
+435.6%
$16
$89
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARWR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Arrowhead Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
63 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
93
Value
91
Momentum
89
Accruals
78
Revisions
49
Volatility
44
Growth
37
Size
14
Issuance
12

Quality (93): The business earns solid, repeatable profits on what it owns.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Arrowhead Pharmaceuticals, Inc. — and when they’d sell — is the membership.

Wall Street

ARWR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARWR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100$120$140Oct 25Jan 26Apr 26Jul 26ARWRHigh $126Median $100Low $95

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $95Median $100High $126

The green dot is the last close — the median target sits +16.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
30 July 2026B. Riley SecuritiesMaintainsBuy$101 → $123
27 July 2026HC Wainwright & Co.MaintainsBuy$100 → $115
23 July 2026Morgan StanleyMaintainsOverweight$100 → $120
23 July 2026Piper SandlerReiteratesOverweight$110 → $126
22 July 2026Chardan CapitalMaintainsBuy$90 → $115
22 July 2026Chardan CapitalMaintainsBuy—
17 July 2026JP MorganMaintainsOverweight$88 → $95
17 July 2026JP MorganMaintainsOverweight—
14 July 2026StifelInitiatesBuy$98
14 July 2026StifelInitiatesBuy—
1 July 2026HC Wainwright & Co.ReiteratesBuy—
30 June 2026Chardan CapitalMaintainsBuy—
17 June 2026Leerink PartnersMaintainsMarket Perform—
13 May 2026BernsteinMaintainsMarket Perform—
8 May 2026RBC CapitalMaintainsOutperform—
1 May 2026JP MorganInitiatesOverweight—
21 Apr 2026Morgan StanleyUpgradeOverweight—
25 Mar 2026HC Wainwright & Co.ReiteratesBuy—
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
22 Jan 2026B. Riley SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

ARWR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Arrowhead Pharmaceuticals, Inc. (ARWR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
47.1×

Cheaper than 16% of US stocks

Price / sales
19.3×

Cheaper than 9% of US stocks

Price / book
19.6×

Cheaper than 5% of US stocks

EV / EBITDA
−58.6×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
−86.4%

Higher than 2% of US stocks

Earnings growth (YoY)
−86.4%

Higher than 4% of US stocks

Gross margin
—
Operating margin
−191.6%

Higher than 11% of US stocks

Net margin
−48.4%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−42.4%

Higher than 23% of US stocks

Return on assets
−7.2%

Higher than 29% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ARWR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARWRArrowhead Pharmaceuticals, Inc.$11.9B
63
BMRNBioMarin Pharmaceutical, Inc.$11.5B
70
CORTCorcept Therapeutics, Inc.$12.3B
78
TECHBio-Techne Corp.$11.2B
88
AXSMAxsome Therapeutics, Inc.$11.2B
74
MDGLMadrigal Pharmaceuticals, Inc.$10.7B
67
SMMTSummit Therapeutics, Inc.$10.4B
18
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARWR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest ARWR news & analysis

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Business Wire · 3 Aug 2026neutral

Arrowhead Pharmaceuticals announced that, on July 16, 2026, its Board of Directors approved inducement grants under NASDAQ Listing Rule 5635(c)(4) to 95 new employees as an inducement to employment. The grants entitle employees, in aggregate, to receive up to 112,794 restricted stock units and are made outside the company's stockholder-approved equity incentive plans.

Why it matters — ARWR watchers would care because the new equity awards to incoming employees signal ongoing hiring and potential dilution outside the company's shareholder-approved compensation plans.

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Business Wire · 27 July 2026positive

Arrowhead Pharmaceuticals announced it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, its investigational RNAi therapeutic for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition causing severely elevated LDL-C and early cardiovascular disease.

Why it matters — Completion of enrollment in a Phase 3 trial moves zodasiran closer to a potential regulatory submission for HoFH, a serious genetic condition with limited treatment options.

FAQ

Frequently asked questions about ARWR stock

What is the ARWR stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Arrowhead Pharmaceuticals, Inc. have a median 12-month price target of $100, with estimates ranging from $95 to $126. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARWR stock a buy right now?

Of the 12 analysts covering Arrowhead Pharmaceuticals, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arrowhead Pharmaceuticals, Inc. 63 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARWR?

As at 1 Aug 2026, Arrowhead Pharmaceuticals, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (93 of 100).

Will ARWR stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +16.3% from the last close, and Ticker Nerd's factor model ranks Arrowhead Pharmaceuticals, Inc. 63 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARWR stock forecast for 2030?

No analyst covering Arrowhead Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARWR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $95 to $126 over the next 12 months.

How has ARWR stock performed over the past year?

Arrowhead Pharmaceuticals, Inc. returned +439.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Arrowhead Pharmaceuticals, Inc. do?

Arrowhead Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing RNA interference-based medicines to treat diseases driven by genetic abnormalities or excess protein production.

What is the latest news on ARWR?

The most recent item we track (Business Wire, 3 Aug 2026): "Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)". Arrowhead Pharmaceuticals announced that, on July 16, 2026, its Board of Directors approved inducement grants under NASDAQ Listing Rule 5635(c)(4) to 95 new employees as an inducement to employment. The grants entitle employees, in aggregate, to receive up to 112,794 restricted stock units and are made outside the company's stockholder-approved equity incentive plans.

Company

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing RNA interference-based medicines to treat diseases driven by genetic abnormalities or excess protein production. The company uses proprietary RNA chemistries and its TRiM platform to selectively silence disease-causing genes across multiple tissues, including liver, lung, muscle, adipose, and central nervous system. Arrowhead’s portfolio spans cardiometabolic and cardiovascular disorders, liver diseases such as alpha-1 antitrypsin deficiency and hepatitis B, pulmonary conditions including idiopathic pulmonary fibrosis and mucus-obstructive lung disease, and rare genetic diseases affecting muscle and complement-mediated pathways. Its first approved product, REDEMPLO (plozasiran), targets familial chylomicronemia syndrome as an adjunct to diet. Beyond wholly owned programs, Arrowhead also collaborates with large pharmaceutical partners to extend the reach of its RNAi therapeutics globally. Founded in 1989 and headquartered in Pasadena, California, with additional R&D and manufacturing facilities in Wisconsin, San Diego, and Ireland, Arrowhead today operates as a specialized player within the biotechnology and healthcare sectors.

CEO Dr. Christopher R. Anzalone Ph.D. · 711 employees · United States · https://arrowheadpharma.com